Barclays analyst Geoffrey Meacham downgraded Incyte to Equal Weight from Overweight and lowered his price target for the shares to $82 from $90. With the stock up 27% year-to-date, the analyst does not see enough upside optionality from the company’s graft-versus-host disease opportunity or its early-stage pipeline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.